NCT02659098View on ClinicalTrials.gov

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 4, 2015

Primary Completion Date

June 5, 2019

Study Completion Date

June 5, 2019

Conditions
Visual AcuityGeographic AtrophyMacular Degeneration
Interventions
DRUG

CNTO 2476 3.0 x 10^5 cells

Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.

DEVICE

Subretinal Delivery System

Participants will receive CNTO 2476 by using the Delivery System.

Trial Locations (8)

Unknown

Arcadia

Chicago

Lexington

Boston

Royal Oak

Cincinnati

Philadelphia

Dallas

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02659098 - A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy | Biotech Hunter | Biotech Hunter